Lantern Pharma Inc (LTRN) is not a strong buy at this moment for a beginner investor with a long-term strategy. The lack of positive financial performance, weak technical indicators, and absence of significant trading trends or catalysts make it unsuitable for immediate investment. It is better to monitor the stock for further developments.

Technical Analysis

The MACD histogram is positive and expanding, suggesting slight bullish momentum. However, RSI is neutral at 58.186, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot level (2.752), with resistance at 2.996 and support at 2.507.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

The low put-call ratios indicate minimal bearish sentiment, but the overall options activity is too low to draw significant conclusions.

Technical Summary

Sell

Buy

Positive Catalysts

NULL identified. No recent news or significant insider/hedge fund activity. AI Stock Picker and SwingMax signals are absent.

Neutral/Negative Catalysts

The company's financial performance is weak, with declining net income (-7.29% YoY) and EPS (-7.14% YoY). There are no recent congress trades or analyst updates. The stock lacks momentum and significant trading trends.

Financial Performance

In 2025/Q3, revenue remained at 0 with no growth. Net income dropped to -$4.18M (-7.29% YoY), and EPS fell to -$0.39 (-7.14% YoY). Gross margin remains at 0, showing no profitability.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No data available for analyst ratings or price target changes.

1 Analyst Rating

Wall Street analysts forecast LTRN stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 2.820

Low

Averages

High

Current: 2.820

Low

Averages

High

Lake Street

Chad Messer

Strong Buy

Initiates

$25

AI Analysis

2025-04-02

Reason

Lake Street

Chad Messer

Price Target

$25

AI Analysis

2025-04-02

Initiates

Strong Buy

Reason

Lake Street initiated coverage of Lantern Pharma with a Buy rating and $25 price target. Lantern's Response Algorithm for Drug Positioning and Rescue, or RADR, platform consists of a suite of AI modules designed to help advance cancer drug development, the analyst tells investors. Unlike many biotech AI platform companies, Lantern is monetizing RADR through advancement of its own pipeline of four clinical, plus additional preclinical, stage molecules, though they also engage in collaborations with partners, adds the analyst, who notes that lead clinical program LP-300 targets a unique set of lung cancer patients who never smoked.

LTRN Should I Buy

LTRN Should I Buy

Should You Buy Lantern Pharma Inc (LTRN) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch